Probiotics as functional food in the treatment of diarrhea

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 6, 2006, Pages 717-721

  Yan, Fang ^a   Polk, D Brent ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Building MRB IV ^*  (United States)

Author keywords

Barrier function; Bifidobacterium; Diarrhea; Intestinal epithelial cell; Lactobacillus; Probiotics; Saccharomyces

Indexed keywords

DN 114001; PROBIOTIC AGENT; ZO 1;

BACTERIAL STRAIN; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG MECHANISM; FOOD; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE EPITHELIUM; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; REVIEW; SACCHAROMYCES; TRAVELLER DIARRHEA; VIRUS INFECTION;

BIFIDOBACTERIUM; DIARRHEA; FOOD MICROBIOLOGY; GASTROINTESTINAL TRACT; HEALTH FOOD; HUMANS; LACTOBACILLUS; PROBIOTICS; SACCHAROMYCES;

BIFIDOBACTERIUM; LACTOBACILLUS; ROTAVIRUS; SACCHAROMYCES;

EID: 33750310556     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000247477.02650.51     Document Type: Review

References (40)

1. Backhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science 2005; 307:1915-1920.
2. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635-1638.
3. Lilly DM, Stillwell RH. Probiotics: growth-promoting factors produced by microorganisms. Science 1965; 147:747-748.
4. Yan F, Polk DB. Commensal bacteria in the gut: learning who our friends are. Curr Opin Gastroenterol 2004; 20:565-571.
5. Brown AC, Valiere A. Probiotics and medical nutrition therapy. Nutr Clin Care 2004; 7:56-68.
6. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001; 73 (2 Suppl):430S-436S.
7. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16:1461-1467.
8. Hawrelak JA, Whitten DL, Myers SP. Is Lactobacillus rhamnosusGG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review. Digestion 2005; 72:51-56. This interesting paper reviews six clinical trials to evaluate the effect of LGG supplementation on prevention of antibiotic-associated diarrhea.
9. Correa NB, Peret Filho LA, Penna FJ, et al. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol 2005; 39:385-389.
10. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:583-590.
11. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812-822. This metaanalysis of probiotics suggests that although S. boulardii and LGG can reduce the incidence of antibiotic-associated diarrhea, only S. boulardii is effective for treatment of diarrhea induced by C. difficile.
12. Szajewska H, Mrukowicz J. Meta-analysis: nonpathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2005; 22:365-372.
13. Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005; 173:167-170.
14. Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C difficile diarrhoea. Int Microbiol 2004; 7:59-62.
15. Allen SJ, Okoko B, Martinez E, et al. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004; (2):CD003048.
16. Szymanski H, Pejcz J, Jawien M, et al. Treatment of acute infectious diarrhoea in infants and children with a mixture of three Lactobacillus rhamnosus strains: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 23:247-253. This paper summarizes the clinical application of probiotics for acute diarrhea in children and adults. The efficacy of probiotics is conflicting, but LGG prevents moderate infectious diarrhea in children.
17. Kurugol Z, Koturoglu G. Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Paediatr 2005; 94:44-47.
18. Salazar-Lindo E, Miranda-Langschwager P, Campos-Sanchez M, et al. Lactobacillus casei strain GG in the treatment of infants with acute watery diarrhea: a randomized, double-blind, placebo controlled clinical trial [ISRCTN67363048]. BMC Pediatr 2004; 4:18.
19. Sarker SA, Sultana S, Fuchs GJ, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics 2005; 116:e221-e228. This study finds L. paracasei strain ST11 does not benefit rotavirus diarrhea.
20. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9. Children fed with formula supplemented with L. reuteri and B. lactis show fewer and shorter episodes of diarrhea.
21. Thibault H, Aubert-Jacquin C, Goulet O. Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004; 39:147-152.
22. Szajewska H, Mrukowicz JZ. Use of probiotics in children with acute diarrhea. Paediatr Drugs 2005; 7:111-122.
23. Ericsson CD. Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea. Clin Infect Dis 2005; 41 (Suppl 8):S557-S563.
24. Roselli M, Finamore A, Britti MS, Mengheri E. Probiotic bacteria Bifidobacterium animalis MB5 and Lactobacillus rhamnosus GG protect intestinal Caco-2 cells from the inflammation-associated response induced by enterotoxigenic Escherichia coli K88. Br J Nutr 2006; 95:1177-1184. This study shows B. animalis and LGG protect intestinal cells from enterotoxigenic E. coli-induced inflammation by preventing enterotoxigenic E. coli adhesion and cytokine and chemokine production.
25. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-382.
26. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17:895-904.
27. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17:687-696. This randomized controlled trial of VSL#3 and placebo shows the beneficial effects of VSL#3 for patients with IBS and bloating.
28. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128:541-551. This novel report shows the advantage of Lactobacillus and Bifidobacterium for alleviating symptoms in IBS may be through downregulating proinflammatory cytokine production.
29. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003; 52:988-997.
30. Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286:G613-G626.
31. Parassol N, Freitas M, Thoreux K, et al. Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res Microbiol 2005; 156:256-262. L. casei inhibits enteropathogenic E. coli-induced increase in intestinal epithelial paracellular permeability.
32. Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-alpha- and IFN-gamma-induced dysfunction in human intestinal epithelial cells. Gastroenterology 2006; 130:731-746. Probiotics prevents cytokine-induced intestinal epithelial cell dysfunction through regulating signaling pathways.
33. Tien MT, Girardin SE, Regnault B, et al. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 2006; 176:1228-1237. L. casei plays an antiinflammatory effect on Shigella-infected human intestinal epithelial cells through NFκB-dependent transcriptional response.
34. Tao Y, Drabik KA, Waypa TS, et al. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol 2006; 290:C1018-C1030. LGG and its soluble factors induce cytoprotective heat shock protein production in intestinal epithelial cells by activation of mitogen-activated protein kinase.
35. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 2001; 1:101-114.
36. Madden JA, Plummer SF, Tang J, et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 2005; 5:1091-1097. Probiotics modulate intestinal microflora during antibiotic therapy.
37. Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005; 26:69-74.
38. Paton AW, Jennings MP, Morona R, et al. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005; 128:1219-1228.
39. Focareta A, Paton JC, Morona R, et al. A recombinant probiotic for treatment and prevention of cholera. Gastroenterology 2006; 130: 1688-1695. Together with Ref. [38], this elegant study shows an engineered probiotic bacterium, recombinant E. coli which produces a chimeric lipopolysaccharide, is capable of binding cholera toxin and protects against virulent V. cholerae infection in infant mice.
40. Sonnenburg JL, Xu J, Leip DD, et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 2005; 307:1955-1959. Host diet regulates commensal bacterial gene expression patterns.